With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M

With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M

Source: 
Xconomy
snippet: 

A cancer tumor is a veritable patchwork of cells with a variety of genetic fingerprints.

Immunitas Therapeutics is using single-cell genomics—an approach that studies the genetic activity of individual cells—to peer deeply into patient tumors and more precisely determine what is fueling the growth.